Michael G. Rosenblum
Professor
Department of Experimental Therapeutics
MD Anderson Cancer Center
United States of America
Biography
Degree-Granting Education: 1978 :University of Arizona College of Medicine, Tucson, AZ, USA, PHD, Pharmacology. 1974 :Medical University of South Carolina, Charleston, SC, USA, MS, Pharmacology 1972 :University of South Carolina, Columbia, SC, USA, BS, Chemistry
Research Interest
Therapeutics, Cancer Medicine, oncology.
Publications
-
Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol Cancer Ther 12 (6) :979-91, 2013
-
Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 98 (2) :217-21, 2013
-
Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC. Mol Cancer Ther 13 (11) :2688-705, 2014
